FDA Approves Tivozanib for Advanced Renal Cell Carcinoma

Tivozanib (Fotivda®, Aveo Pharmaceuticals, Inc.) has been approved by the FDA for adult patients with relapsed/refractory advanced renal cell carcinoma (RCC) who were previously treated with at least two systemic therapies. "Treatment for RCC has been revolutionized by inhibitors of the vascular endothelial growth factor receptor (VEGFR)," wrote the investigators of TIVO-3 (NCT02627963), the trial on which the approval was based, led by Brian Rini, MD, Chief of Clinical Trials at the Vander...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.